<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Dec. 5, 2019 (HealthDay News) — For patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an EGFR<\/i> mutation, overall survival is longer for treatment with osimertinib rather than comparator tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKIs), according to a study published online Nov. 21 in the New England Journal of Medicine<\/i>.<\/p>\n
Suresh S. Ramalingam, M.D., from the Emory University School of Medicine in Atlanta, and colleagues randomly assigned 556 patients with previously untreated advanced NSCLC with an EGFR<\/i> mutation to receive either osimertinib or one of two other EGFR-TKIs (gefitinib or erlotinib) combined into a single comparator group.<\/p>\n
The researchers found that the median overall survival was 38.6 and 31.8 months in the osimertinib and comparator groups, respectively (hazard ratio for death, 0.80; 95.05 percent confidence interval, 0.64 to 1.00; P = 0.046). At three years, 28 and 9 percent of patients in the osimertinib and comparator groups, respectively, were still receiving a trial regimen; median exposure was 20.7 and 11.5 months, respectively. Forty-two percent of patients in the osimertinib group and 47 percent in the comparator group had adverse events of grade 3 or higher.<\/p>\n
“We found that first-line treatment with osimertinib was associated with significantly longer overall survival than treatment with comparator EGFR-TKIs in patients with EGFR<\/i> mutation-positive, locally advanced or metastatic NSCLC and had a similar safety profile,” the authors write.<\/p>\n
Several authors disclosed financial ties to AstraZeneca, which manufactures osimertinib and funded the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n